Autoimmune Diseases
Conference Coverage
Lupus patients in remission see more flares with HCQ reduction, discontinuation
It’s clear that more flares occur when patients with lupus in remission or low disease activity stop hydroxychloroquine or reduce its dosing, but...
Conference Coverage
Rituximab improves systemic sclerosis skin, lung symptoms
Patients who took rituximab in the DESIRES trial had better skin scores and lung function at 6 months than did patients who received placebo.
Clinical Review
Management of Acute and Chronic Pain Associated With Hidradenitis Suppurativa: A Comprehensive Review of Pharmacologic and Therapeutic Considerations in Clinical Practice
This comprehensive review provides an update on current treatment of hidradenitis suppurativa–associated pain, including a summary of existing...
Conference Coverage
Vitamin D and omega-3 supplements reduce autoimmune disease risk
“People who are otherwise healthy and have a family history of autoimmune disease might also consider starting to take these supplements.”
Conference Coverage
‘Multimorbidity’ more commonly seen in people with lupus
Two studies find that patients with either systemic or cutaneous disease have higher rates of multiple comorbidities, including those commonly...
Cosmeceutical Critique
The tryptophan photoproduct FICZ and its effects on the skin
Much more research is necessary to determine how best to harness and direct the useful activities of tryptophan and FICZ without incurring...
Conference Coverage
Lupus may confer higher risk of death from COVID-19
SLE had a greater impact on mortality and other poor outcomes than did all the other comorbidities considered in a cross-sectional study of COVID-...
Original Research
Duration of Adalimumab Therapy in Hidradenitis Suppurativa With and Without Oral Immunosuppressants
Although combining tumor necrosis factor α inhibitors with oral immunosuppressants such as methotrexate and mycophenolate mofetil appears to be...
News from the FDA/CDC
FDA approves avacopan for rare ANCA autoimmune disease
ChemoCentryx said it plans to price its new medicine at an annual cost of $150,000-$200,000 for U.S. patients.
Feature
NIAMS director reflects on her mentors, spotlights research projects underway
“Ultimately, I want to contribute to the great work of the Institute and improve the lives of people with rheumatic, musculoskeletal, and skin...
From the Journals
Temporary hold of mycophenolate helps immune response to SARS-CoV-2 vaccination
A comparison of patients with rheumatic and musculoskeletal diseases shows that withholding mycophenolate around the time of vaccination can be...